Septerna Posts $26.6M Q3 Loss on Lower Revenue
The South San Francisco biotech reported a third-quarter 2026 net loss as research spending rose and prior-year revenue from a Novo Nordisk deal declined.
Updated on Nov. 9, 2026 in Corporate Finance

Septerna reported third-quarter 2026 revenue of $18.9 million, down from $21.5 million a year earlier, and a net loss of $26.6 million, compared with net income of $8.2 million in the same period of 2025. The company ended the quarter with $565.2 million in cash, cash equivalents, and marketable securities.
Why it matters
The swing from profit to loss was driven largely by higher research and development spending, which rose to $36.6 million from $24.3 million a year earlier. For a South San Francisco biotech, the cash position and runway projections signal how long the company can fund its pipeline without new financing.
Septerna's third-quarter 2026 revenue of $18.9 million included $2.7 million of amortization from the $195.0 million Novo Nordisk upfront payment, $5.2 million from research milestones and $11.0 million for research services. Cash, equivalents and marketable securities stood at $565.2 million, but the filing does not detail how that balance will be allocated beyond the stated runway into mid-2029.
The players
Septerna
A South San Francisco biotechnology company focused on small-molecule therapeutics targeting G protein-coupled receptors, with a collaboration with Novo Nordisk.
Novo Nordisk
A Danish pharmaceutical company and Septerna collaboration partner that paid a $195.0 million upfront payment, the amortization of which is recognized in Septerna's revenue.
The details
Septerna reported a net loss for the quarter ended September 30, 2026, after general and administrative expenses of $9.6 million and research and development expenses of $36.6 million. The company also selected SEP-204 as its oral TSHR negative allosteric modulator development candidate during the period.
Timeline
September 30, 2025: Prior-year quarter comparison period ended.
September 30, 2026: Third-quarter 2026 reporting period ended.
November 9, 2026: Septerna released third-quarter 2026 results.
Market Dynamics
Septerna's swing from a $8.2 million profit in the third quarter of 2025 to a $26.6 million loss in 2026 reverses the earnings position it held a year earlier. The shift reflects a pipeline phase in which spending on research outpaces the one-time upfront revenue recognized from its collaboration with Novo Nordisk.
For investors and employees tracking the company, the filing shows that cash on hand is expected to fund operations into mid-2029 despite the quarterly loss. Shareholders should watch whether the Q1 2027 clinical milestones arrive on schedule, since those readouts will shape near-term funding needs.
The takeaway
A quarterly loss from a biotech does not by itself signal distress when cash balances are large and the runway is stated; the key test is whether upcoming trial milestones are met on the timetable the company has set.
What happens next
Septerna expects to initiate a Phase 1 clinical trial of SEP-204 in Q1 2027, and SAD / MAD data for SEP-479 are expected in the same quarter.
Further reading
Explore more Corporate Finance coverage for context on how biotech companies manage cash runways and collaboration revenue.
Source note: This article includes information reported by The Manila times.










